I don't think the anchor market has changed at all, last I heard it was still around 40M patients. If amarin gets expanded label, then it seems that its all theirs for the taking except for off label scripts involving Lovaza and generic. Back to pre adcom level immediately is my take with a positive FDA outcome. Not sure NCE will have that much impact at this late stage, but patent infringement fight with AZN will prove patent strength, and NCE loses its significants....all IMHO of course!
News 
Market Data 
Discover 
